DUBLIN–(BUSINESS WIRE)–The “Global Doxorubicin Market Report and Forecast 2023-2031” report has been added to ResearchAndMarkets.com’s offering.
The global doxorubicin market size attained a value of USD 1218 million in 2022. The market is anticipated to grow at a CAGR of 6.4% during the forecast period of 2023-2031 to attain a value of USD 2128.8 million by 2031.
Doxorubicin, also known as Adriamycin or hydroxydaunorubicin, is a chemotherapy drug belonging to the class of anthracycline antibiotics. It is derived from the Streptomyces peucetius bacterium and is known for its red colour. [Doxorubicin is used primarily in the treatment of a wide range of cancers, including breast cancer, ovarian cancer, lung cancer, stomach cancer, thyroid cancer, bladder cancer, multiple myeloma, Hodgkin’s lymphoma, and non-Hodgkin’s lymphomas.
The drug works by intercalating into DNA, which prevents the replication of cancer cells and eventually leads to cell death. Doxorubicin also inhibits the enzyme topoisomerase II, which is involved in DNA replication and transcription, further contributing to the drug’s anticancer effects.
The global market for doxorubicin is expected to continue to grow in the coming years, driven by an increasing incidence of cancer and a growing demand for effective treatments. In addition, the development of new formulations and delivery methods for doxorubicin is expected to further drive market growth. For example, liposomal doxorubicin, a type of doxorubicin that is encapsulated in a lipid membrane, has been shown to be more effective and less toxic than conventional doxorubicin in some cases.
However, the market for doxorubicin is also facing challenges, including the high cost of treatment and the potential for serious side effects. In addition, the emergence of alternative therapies, such as immunotherapy and targeted therapies, may limit the growth of the doxorubicin market in the coming years. Nevertheless, doxorubicin remains an important and widely used chemotherapy drug, and its continued development and use will play an important role in the fight against cancer.
The benefits of doxorubicin include:
1. Broad-spectrum activity: It is effective against a wide range of cancer types, making it a valuable treatment option for many patients.
2. Combination therapy: Doxorubicin is often used in combination with other chemotherapy drugs, enhancing their effectiveness and improving treatment outcomes.
3. Proven effectiveness: Doxorubicin has a long history of use in cancer treatment and has been proven effective in various clinical trials and studies.
However, doxorubicin has several side effects and risks, including heart damage (cardiotoxicity), bone marrow suppression, nausea, vomiting, hair loss, and mouth sores. The risk of cardiotoxicity increases with cumulative doses, so the total amount of doxorubicin a patient can receive during their lifetime is limited. Doctors and healthcare providers closely monitor patients receiving doxorubicin to manage side effects and minimize risks.
Doxorubicin Market Segmentation
The market can be categorised into application, distribution channel, and regions.
by Application
- Ovarian Cancer
- Multiple Myeloma
- Kaposi Sarcoma
- Leukaemia
- Bone Sarcoma
- Breast Cancer
- Endometrial Cancer
- Gastric Cancer
- Liver Cancer
- Kidney Cancer
- Other Cancers
by Distribution Channel
- Market Overview
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
by Region
North America
- United States of America
- Canada
Europe
- United Kingdom
- Germany
- France
- Italy
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Players in the Global Doxorubicin Market
The report gives an in-depth analysis of the key players involved in the doxorubicin market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Pfizer Inc
- Sun Pharmaceutical Industries Limited
- Cipla, Inc
- Cadila Pharmaceuticals Ltd
- SRS PHARMACEUTICALS PVT. LTD.
For more information about this report visit https://www.researchandmarkets.com/r/84s3se
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900